A study presented at the European Academy of Dermatology and Venereology Congress compared the effectiveness of risankizumab with other biologics in treating psoriasis. The study included biologic-naïve and biologic-experienced patients with moderate to severe psoriasis. Results showed that risankizumab significantly improved psoriasis severity and quality of life in both groups of patients. At week 100, more patients in the risankizumab groups achieved PASI 100 compared to those in other biologic groups. The study highlighted the importance of assessing real-world effectiveness of treatment options to understand their impact on patients’ quality of life and disease severity.
Source link
Risankizumab shows real-world efficacy in psoriasis
